Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
XTLB
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
9 hours ago
globenewswire.com
9 hours ago
globenewswire.com
9 hours ago
globenewswire.com
10 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Relative Strength
XTLB
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.04Ā ( -2.86%)
Relative Strenght
22
Volume Buzz
-65%
Earning Acce
Yes
Dist 52w H.
47%Earnings Growth
YoY
Current
Estimates
Q3.22
N/A
-0.15
vsĀ -0.00
Q4.22
N/A
-0.14
vsĀ 0.4
Q1.23
N/A
-0.17
vsĀ 0
Q2.23
N/A
-0.07
vsĀ -0.10
Q3.23
N/A
-0.04
vsĀ -0.15
Q4.23
N/A
NA
vsĀ -0.14
Q1.24
+159%
0.1
vsĀ -0.17
Q2.24
N/A
-0.07
vsĀ -0.07
Q3.24
N/A
-0.13
vsĀ -0.04
Q4.24
N/A
NA
vsĀ NA
Sales Growth
YoY
Current
Estimates
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
162KĀ vsĀ NA
Q4.24
NA
289KĀ vsĀ NA
Return on Equity
QoQ
Q3.22
-17%
-0.17
vsĀ -0.05
Q4.22
-19%
-0.19
vsĀ -0.17
Q1.23
-30%
-0.30
vsĀ -0.19
Q2.23
-13%
-0.13
vsĀ -0.30
Q3.23
-9%
-0.09
vsĀ -0.13
Q4.23
-13%
-0.13
vsĀ -0.09
Q1.24
+18%
0.18
vsĀ -0.13
Q2.24
-32%
-0.32
vsĀ 0.18
Q3.24
-10%
-0.10
vsĀ -0.32
Q4.24
-5%
-0.05
vsĀ -0.10
Institutionnal Ownership
QoQ
Q1.23
2
2
vsĀ 3
-33%
Q2.23
3
3
vsĀ 2
50%
Q3.23
4
4
vsĀ 3
33%
Q4.23
5
5
vsĀ 4
25%
Q1.24
5
5
vsĀ 5
NA
Q2.24
4
4
vsĀ 5
-20%
Q3.24
3
3
vsĀ 4
-25%
Q4.24
3
3
vsĀ 3
NA
Q1.25
4
4
vsĀ 3
33%
Q2.25
3
3
vsĀ 4
-25%